false
English
Catalog
2024 World Conference on Lung Cancer (WCLC) - Post ...
P2.11C.01 With Eyes on the Future: Prospective Eva ...
P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer
Back to course
Pdf Summary
This ongoing study, conducted by researchers at the Dana-Farber Cancer Institute and Harvard Medical School, aims to evaluate immune-related adverse events (irAEs) in lung cancer (LC) patients undergoing immunotherapy with immune checkpoint inhibitors (ICIs). The research provides a real-world assessment of ICI tolerability, an area previously lacking comprehensive data.<br /><br />The study involves 36 patients from Dana-Farber with lung cancer stages I to IV, receiving single-agent immunotherapy. Different ICIs used include Pembrolizumab (50%), Durvalumab (19.4%), with smaller percentages for other ICIs like Nivolumab, Atezolizumab, and Ipilimumab. Data is collected using the ePRO-CTCAE tool at multiple points during treatment and includes demographics and patient-reported symptoms.<br /><br />Key findings from this report include frequent high-severity symptoms such as shortness of breath and coughing. Other symptoms of note, albeit less common, include severe nausea and abdominal pain. Fatigue or a lack of energy was prevalent, affecting 27 out of 34 patients. Anorexia was reported by 14 patients, with 8 noting it interfered significantly with their daily activities. Other symptoms like diarrhea, dry mouth, and difficulty tasting were noted but were less frequent.<br /><br />The study is significant as it provides prospective evaluations of irAEs linked to ICIs in patients with lung cancer. Understanding the time-dependent nature of these adverse events is vital for improving patient management. Further investigation into how these symptoms evolve over time is planned to enhance patient care and management strategies as the study progresses.
Asset Subtitle
Lauren Kiel
Meta Tag
Speaker
Lauren Kiel
Topic
Metastatic NSCLC – Immunotherapy
Keywords
immune-related adverse events
lung cancer
immunotherapy
immune checkpoint inhibitors
Pembrolizumab
Durvalumab
patient-reported symptoms
Dana-Farber Cancer Institute
Harvard Medical School
ICI tolerability
×
Please select your language
1
English
5
普通话
11
Dutch